Stratifies NAFLD Patients
And Diagnoses NASH Accurately

Diagnose NASH With LIVERFASt™

LIVERFASt™ is a blood-based test that provides a complete liver assessment and diagnosis for fibrosis, activity, and steatosis from early to late NASH stages.

LIVERFASt™ Identifies NAFLD Among Patients With MetS

The median scores of LIVERFASt™ tests increase with the number of MetS factors.

LIVERFASt™ stratifies NAFLD according to fibrosis, activity, and steatosis stages.

LIVERFASt™ performs similarly for patients with obesity and diabetes.

mets diagram

Reliable Results Compared To Elastography

LIVERFASt™ provides reliable results in patients with conditions where liver stiffness measurement by elastography could not:

Severe obesity (risk of failure of elastography).

Severe steatosis (risk of overestimation of liver stiffness).

Significant liver inflammation (risk of overestimation of liver stiffness).

LIVERFASt™ Outperforms Other Standards Of Care

LIVERFASt™ provides higher accuracy for cirrhosis in both diabetic and non-diabetic patients:

For severe fibrosis and cirrhosis:

Performed comparably to elastography with better applicability and no failure.

Outperformed FIB-4 in the identification of cirrhosis and severe fibrosis in Type 2 Diabetes NAFLD patients.

For early fibrosis: better performance than elastography without bias from inflammatory activity and steatosis.

For steatosis: better grading of steatosis than liver ultrasound and controlled attenuation parameter (CAP).

Learn more about integrating LIVERFASt™ in your clinic

References

Chalassani N, et al. Hepatology. 2018 Jan;67:328-357.
Younossi ZM, et al. Hepatology. 2016;64:73–84.
Aravind A, et al. JILSA. 2020;12:31-49.
De Lédinghen V, et al. Hepatology 2020.72;1:906A
Raskin M, et al. Hepatology 2020.72;1:273A

Cohn B, et al. Hepatology 2020.72;1:943A
De Ledinghen V, et al. J Hepatol 2021:#198 (abstract)
Ratziu V, et al. 2005 Jun;128:1898-906.
Diehl AM, et al. NEJM. 2017; 377: 2063-2072.
Wong RJ, et al. Gastroenterology. 2015;148: 547-55.